Ovid Therapeutics Inc.OVIDNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-146.86%
↓ 3326% below average
Average (39q)
4.55%
Historical baseline
Range
High:917.73%
Low:-351.47%
Volatility
27876.5%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -146.86% |
| Q2 2025 | 59.58% |
| Q1 2025 | -17.05% |
| Q4 2024 | 18.93% |
| Q3 2024 | 35.54% |
| Q2 2024 | -17.80% |
| Q1 2024 | 4.24% |
| Q4 2023 | -51.20% |
| Q3 2023 | 15.12% |
| Q2 2023 | 4.83% |
| Q1 2023 | -22.34% |
| Q4 2022 | 4.93% |
| Q3 2022 | 10.49% |
| Q2 2022 | 12.07% |
| Q1 2022 | 38.27% |
| Q4 2021 | -125.60% |
| Q3 2021 | 18.38% |
| Q2 2021 | -108.11% |
| Q1 2021 | 917.73% |
| Q4 2020 | -31.62% |
| Q3 2020 | 29.12% |
| Q2 2020 | -14.03% |
| Q1 2020 | -17.53% |
| Q4 2019 | -2.99% |
| Q3 2019 | -25.85% |
| Q2 2019 | 5.21% |
| Q1 2019 | -7.14% |
| Q4 2018 | 0.45% |
| Q3 2018 | 0.26% |
| Q2 2018 | 1.64% |
| Q1 2018 | -21.56% |
| Q4 2017 | -17.42% |
| Q3 2017 | 8.54% |
| Q2 2017 | 69.97% |
| Q1 2017 | -351.47% |
| Q4 2016 | -30.51% |
| Q3 2016 | -7.35% |
| Q2 2016 | -45.85% |
| Q1 2016 | -10.90% |
| Q4 2015 | 0.00% |